Zoek in het archief
 
terug

Check the original
News breaking: 2017-07-10

MIT en Harvard nemen deel aan licentiepool CRISPR-Cas9 van MPEG LA

17:27 uur 10-07-2017

MIT en Harvard nemen deel aan licentiepool CRISPR-Cas9 van MPEG LA

DENVER–(BUSINESS WIRE)– MPEG LA, LLC, wereldwijd toonaangevend in licenties, heeft vandaag met blijdschap bekendgemaakt dat houders van belangrijke patenten op CRISPR patenten hebben ingediend. Dit gebeurde nadat MPEG LA een oproep had gedaan voor deelname aan het gezamenlijke licentieplatform CRISPR-Cas9. Patenten worden nog steeds toegelaten. “De enthousiaste reacties op het initiatief voor een patentpool van MPEG LA onderschrijven eens te meer de breed gedeelde opvatting dat CRISPR te belangrijk is voor een eindeloze patentstrijd en versplinterde licentieprogramma’s. Met de efficiëntie en voorspelbaarheid van één enkele licentie voor wetenschappers en bedrijven over de hele wereld is de kans op volledige verwezenlijking van alle kansen op een beter leven het grootst”, zei Larry Horn, president en ceo van MPEG LA. “Omdat MPEG LA zich ten doel stelt zo veel mogelijk intellectueel eigendom met betrekking tot CRISPR wereldwijd beschikbaar te stellen en alle betrokkenen op de markt profiteren van deze kans om de toekomst van CRISPR mede te bepalen, blijven extra patentinzendingen welkom.”

The Broad Institute of MIT and Harvard Among Those Participating in MPEG LA’s CRISPR-Cas9 Joint Licensing Facilitation

DENVER–(BUSINESS WIRE)– World licensing leader MPEG LA, LLC is pleased to announce that key CRISPR patent holders have submitted patents in response to MPEG LA’s call to participate in the creation of a global CRISPR-Cas9 Joint Licensing Platform and that patent submissions continue to be accepted.

“The enthusiastic response to MPEG LA’s patent pool initiative is further evidence of the widely held view that CRISPR is too important to be left at risk of endless patent battles and splintered licensing regimes and that a pool providing one-stop licensing efficiency and predictability to scientists and businesses worldwide represents the best hope to unleash its life-enhancing potential,” said Larry Horn, President and CEO of MPEG LA. “As MPEG LA’s objective is to provide worldwide access to as much CRISPR intellectual property as possible and the market will benefit from the viewpoints of all stakeholders in this voluntary ground floor opportunity to determine CRISPR’s future, the door remains open and additional patent submissions continue to be welcomed.”

Among those who have agreed to participate, MPEG LA welcomes the Broad Institute of MIT and Harvard, which has submitted key CRISPR-Cas9 patents for consideration with joint owners Harvard University, the Massachusetts Institute of Technology, and The Rockefeller University.

“We strongly support making CRISPR technology broadly available,” said Issi Rozen, Chief Business Officer of the Broad Institute. “The Broad Institute already licenses CRISPR-Cas9 non-exclusively for all applications, with the exception of human therapeutics, where we have significantly limited the exclusivity. We look forward to working with others to ensure the widest possible access to all key CRISPR intellectual property.”

“Regardless of the outcome of the various legal and administrative proceedings in the United States and Europe, many CRISPR patents owned by many different entities will be left standing and multiple licenses will still be necessary,” added Kristin Neuman, Executive Director, Biotechnology Licensing at MPEG LA. “Companies performing research and development the world over, including those who currently hold exclusive licenses, will benefit from the transparency of a pool and the ability to license the necessary patents in a single transaction on fair and predictable terms.”

Patent holders are encouraged to visit http://www.mpegla.com/main/pid/CRISPR/default.aspx for the terms and procedures governing submissions and eligibility. At least one eligible patent asset is necessary to participate in the license development process, and eligibility will be determined by MPEG LA at no cost to submitters. Except for confidentiality, participation is without obligation or commitment until such time as an eligible patent holder may decide to join the license.

MPEG LA, LLC

MPEG LA is the world’s leading provider of one-stop licenses for standards and other technology platforms. Starting in the 1990s, it pioneered the modern-day patent pool helping to produce the most widely used standards in consumer electronics history. MPEG LA has operated licensing programs for a variety of technologies consisting of more than 14,000 patents in 84 countries with some 230 patent holders and more than 6,000 licensees. By assisting users with implementation of their technology choices, MPEG LA offers licensing solutions that provide access to fundamental intellectual property, freedom to operate, reduced litigation risk and predictability in the business planning process. In turn, this enables inventors, research institutions and other technology owners to monetize and speed market adoption of their assets to a worldwide market while substantially reducing the cost of licensing. MPEG LA is developing patent pools for CRISPR gene editing and advanced battery technologies, and has established licensing ventures for molecular diagnostics and oligonucleotide therapeutics. For more information, go to www.mpegla.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170710005407/en/

Contacts

MPEG LA, LLC

Tom O’Reilly, 303-200-1710

Fax: 301-986-8575

toreilly@mpegla.com

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.